Mode
Text Size
Log in / Sign up
Phase 2 N=36 Randomized Triple-blind Treatment

Transcutaneous Vagus Nerve Stimulation (tVNS) and Robotic Training to Improve Arm Function After Stroke

Stroke · Cerebrovascular Accident (CVA) · Hemiparesis

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Median Absolute Change From Baseline in Electromyographic (EMG) Peak Amplitude of the Bicep/Tricep — 22.310; 7.010; 16.070; 10.055 percentage of MVC — p=0.002

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Transcutaneous Vagus Nerve Stimulation (tVNS) (Device); Sham Transcutaneous Vagus Nerve Stimulation (tVNS) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Northwell Health
Primary completion
Jun 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Median Absolute Change From Baseline in Electromyographic (EMG) Peak Amplitude of the Bicep/Tricep
22.310; 7.010; 16.070; 10.055; 21.730; 13.545 0.002 sig
SECONDARY
Median Change From Baseline in Upper Extremity Fugl Meyer Assessment Score
2.000; 2.500; 2.330; 1.670 1.000

Summary

The purpose of this study is to evaluate if multiple therapy sessions of Transcutaneous Vagus Nerve Stimulation (tVNS) combined with robotic arm therapy lead to a greater functional recovery in upper limb mobility after stroke than that provided by robotic arm therapy in a sham stimulation condition.

Eligibility Criteria

Inclusion Criteria

  • Individuals between 18 and 85 years of age
  • First single focal unilateral supratentorial ischemic stroke with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior
  • Cognitive function sufficient to understand the experiments and follow instructions (per interview with Speech Pathologist or PI)
  • Fugl-Meyer assessment 12 to 44 out of 66 (neither hemiplegic nor fully recovered motor function in the muscles of the shoulder, elbow, and wrist).

Exclusion Criteria

  • Botox treatment within 3 months of enrollment
  • Fixed contraction deformity in the affected limb
  • Complete and total flaccid paralysis of all shoulder and elbow motor performance
  • Prior injury to the vagus nerve
  • Severe dysphagia
  • Introduction of any new rehabilitation interventions during study
  • Individuals with scar tissue, broken skin, or irremovable metal piercings that may interfere with the stimulation or the stimulation device
  • Highly conductive metal in any part of the body, including metal injury to the eye; this will be reviewed on a case by case basis for PI to make a determination
  • Pregnant or plan on becoming pregnant or breastfeeding during the study period
  • Significant arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, sick sinus syndrome, and A-V blocks (enrollment to be determined by PI review)
  • Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system; Loop recorders will be reviewed on a case by case basis by PI and the treating Cardiologist to make a determination
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03592745). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search